Roidipedia.Compound reference & reporting
05 AUG 2026
CompoundsPharmaceutical Ezetimibe
PharmaceuticalCardiovascularCholesterol-absorption inhibitorLipid-lowering

Ezetimibe

Also known as Zetia · Ezetrol

Ezetimibe is a cholesterol-absorption inhibitor that lowers LDL by blocking intestinal uptake of dietary and biliary cholesterol. PED users use it, often alongside or instead of a statin, to counter the LDL rise driven by anabolic steroids, particularly harsh orals. It has solid clinical trial data, including cardiovascular outcome benefit when added to statin therapy.

01 Overview

Ezetimibe acts on the NPC1L1 transporter in the small intestine, reducing cholesterol absorption and prompting the liver to up-regulate LDL receptors and clear more LDL from the blood. As monotherapy it lowers LDL by roughly 15-20%; added to a statin it produces further reductions and, in the IMPROVE-IT trial, modestly improved cardiovascular outcomes.

Because its mechanism is independent of the liver-based HMG-CoA pathway, PED users sometimes prefer it where they wish to avoid or minimise statin dosing, or combine it with a low statin dose to control steroid-driven LDL. It is generally well tolerated, with a low incidence of the myalgia that troubles some statin users.

02 Mechanism

Inhibits the intestinal NPC1L1 sterol transporter, reducing absorption of dietary and biliary cholesterol; the liver responds by up-regulating LDL receptors and clearing more circulating LDL.

03 Dosing

TierDoseRouteNotes
On-cycle LDL control10 mg/dayOralUsed to blunt steroid-driven LDL rise, often with a low statin dose.
Hyperlipidaemia (label)10 mg/dayOralSingle fixed 10 mg once-daily dose, alone or with a statin.

04 Effects

EffectMagnitudeEvidence
Reduced LDL cholesterolLowers LDL by blocking intestinal cholesterol absorption; additive to statins.-15 to -20% mono; more with statinClinical
Cardiovascular outcome benefitAdded to statin therapy it modestly reduced cardiovascular events in high-risk patients.modest (IMPROVE-IT)Clinical

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
MyalgiaMuscle aches, less frequent than with statins.MildUncommonClinical
Transaminase elevationSmall rises in liver enzymes, more likely combined with a statin.MildUncommonClinical

07 References

IMPROVE-IT: ezetimibe added to simvastatinN Engl J Med, 2015
Zetia (ezetimibe) FDA prescribing informationUS FDA

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.